Talha Badar: Latest paper from COMMAND real-world consortium
Talha Badar shared a post on X about a recent paper published in American Journal of Hematology.
Authors: Talha Badar, Ravi Narra, Alice Mims, Ehab Atallah, Mark Litzow et al.
“Happy to share latest paper from our COMMAND real-world consortium; one of the largest RWD looking at outcome of Ph+ ALL patients in the contemprary era.
Ph+ ALL (RWD)
Intensive chemotherapy (IC) combination with 2nd or 3rd generation TKI improves survival compared to non-IC with 1st generation TKI.
The 3-year OS based on TKI used during induction was 55.7% and 71.1% with 1st and 2nd/3rd generation TKI, respectively (HR 0.66, p= 0.026).
Relapse free survival (Ph+ve ALL RWD)
Allo-HCT showed favorable impact on RFS irrespective of patients achieving CMR (HR; 0.32, p= <0.001) or not achieving CMR at 3 months (HR; 0.22, p= <0.001).
Overall survival (Ph+ve ALL RWD)
Allo-HCT did not show significant impact on OS based on achieving CMR (HR; 0.87, p= 0.59) or not achieving CMR (HR; 0.48, p= 0.11) at 3 months. We did not observe significant improvement in OS with allo-HCT at 180-day time point (HR; 0.75, p=0.09).
Ph+ve ALL RWD
MFC-MRD post induction and CMR (0.01 or lower) at 3 month, not predictive of RFS or OS in MVA.
Ph+ve ALL RWD (COMMAND consortium)
Summary:
- We observed significantly inferior RFS and OS for older age at diagnosis (>61 vs. ≤ 40 years), and use of 1st generation vs. 2nd/3rd generation TKI during induction.
- In MVA, the regimen intensity (NIC vs. IC) did not appear to retain significance for RFS or OS.
- Allogeneic stem cell transplantation was beneficial in improving RFS but not OS in patients who achieve CMR at 3 months.
I can’t thank enough to all collaborators!! Rory Shallis, Anand Patel, Adam DuVall, Vamsi Kota, Emily Curran, Mark Litzow others not on twitter/X Dr. Advani, Dr. Atallah, Dr. Alice Mims, Dr. Neil Palmisiano et al.”
Source: Talha Badar/X
More posts featuring Talha Badar on oncodaily.com
Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023